BEDFORD, Mass. - Ocular Therapeutix, Inc. (NASDAQ: NASDAQ:OCUL), a biopharmaceutical company valued at $1.28 billion, has made significant strides in its clinical trials for AXPAXLI™, a treatment for wet age-related macular degeneration (wet AMD (NASDAQ:AMD)), and plans to extend its application to diabetic retinopathy. The SOL-1 trial for wet AMD completed its randomization phase in December 2024, and the SOL-R trial has enrolled 311 subjects as of January 10, 2024. Topline data from SOL-1 is expected in the fourth quarter of 2025, and the company intends to consult with the FDA on trial designs for AXPAXLI in non-proliferative diabetic retinopathy (NPDR) during the first half of 2025. Despite recent market volatility causing a 10.5% decline in the past week, the stock has delivered an impressive 85% return over the last year, according to InvestingPro data.
Wet AMD is a leading cause of blindness, particularly among older adults in the United States. Ocular Therapeutix is aiming to redefine treatment standards for this condition and NPDR, which is a common cause of vision loss in the working-age population. The company's HELIOS study demonstrated that a single injection of AXPAXLI significantly reduced the risk of vision loss in NPDR patients at 48 weeks. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 13.01 and holds more cash than debt on its balance sheet, providing financial flexibility to advance its clinical programs.
The SOL-1 study is a superiority trial comparing AXPAXLI to aflibercept injections in treatment-naïve wet AMD subjects. The trial has been conducted under a Special Protocol Agreement with the FDA. The SOL-R study is a non-inferiority trial comparing repeated AXPAXLI injections to aflibercept, with a primary endpoint of 56 weeks.
Ocular Therapeutix's approach to treatment is based on the ELUTYX™ technology, which utilizes a bioresorbable hydrogel for the delivery of medication. AXPAXLI, incorporating axitinib, is designed to inhibit abnormal blood vessel growth in the eye, which is a key factor in wet AMD and other retinal diseases.
Physicians involved in the trials have expressed optimism about the potential of AXPAXLI to reduce treatment burden and improve patient outcomes. If approved, AXPAXLI could offer an extended durability of 6-12 months between treatments. This development could significantly impact the management of wet AMD and diabetic retinopathy, potentially benefiting millions of patients worldwide. Analysts share this optimism, with price targets ranging from $14 to $22 per share, suggesting significant upside potential. For deeper insights into Ocular Therapeutix's financial health, growth prospects, and comprehensive analysis, investors can access the full Pro Research Report available on InvestingPro, which covers over 1,400 US equities with detailed metrics and expert analysis.
This report is based on a press release statement from Ocular Therapeutix, Inc.
In other recent news, Ocular Therapeutix has been making significant strides in its clinical trials for AXPAXLI, a treatment for wet age-related macular degeneration (AMD). H.C. Wainwright and Baird have both maintained their Buy and Outperform ratings respectively, with H.C. Wainwright raising the stock price target to $15. The company's Phase 3 SOL-1 trial has fully enrolled and randomized over 300 patients, and the SOL-R trial is seeing accelerated enrollment rates.
Ocular Therapeutix reported a total revenue of $15.4 million in its third-quarter financial report, a 2.3% year-over-year increase, albeit lower than the anticipated $16.8 million. Net losses were reported at $36.5 million. The company's lead product, DEXTENZA, is projected to generate between $62 million and $67 million in revenue for the full year of 2024.
These developments are backed by a robust cash position of approximately $427 million. The company anticipates releasing topline results from the SOL-1 trial in the fourth quarter of 2025. These recent developments underscore Ocular Therapeutix's commitment to advancing AXPAXLI's clinical development and exploring treatment options for retinal diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.